Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial.

@article{LpezMedina2021EffectOI,
  title={Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial.},
  author={E. L{\'o}pez-Medina and P. L{\'o}pez and I. Hurtado and D. D{\'a}valos and Oscar Ram{\'i}rez and Ernesto Mart{\'i}nez and J. Diazgranados and J. O{\~n}ate and Hector Chavarriaga and S. Herrera and B. Parra and G. Libreros and R. Jaramillo and A. C. Avenda{\~n}o and Dilian Toro and M. Torres and M. C. Lesmes and Carlos A R{\'i}os and Isabella Caicedo},
  journal={JAMA},
  year={2021}
}
Importance Ivermectin is widely prescribed as a potential treatment for COVID-19 despite uncertainty about its clinical benefit. Objective To determine whether ivermectin is an efficacious treatment for mild COVID-19. Design, Setting, and Participants Double-blind, randomized trial conducted at a single site in Cali, Colombia. Potential study participants were identified by simple random sampling from the state's health department electronic database of patients with symptomatic, laboratory… Expand

Figures and Tables from this paper

Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial
TLDR
Ivermectin had no significant effect on preventing hospitalization of patients with COVID-19 and patients who received ivermECTin required invasive MVS earlier in their treatment. Expand
Single-dose oral ivermectin in mild and moderate COVID-19 (RIVET-COV): A single-centre randomized, placebo-controlled trial
Introduction Ivermectin is an antiparasitic drug which has in-vitro efficacy in reducing severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) viral load.Expand
Antiviral effect of high-dose ivermectin in adults with COVID-19: A proof-of-concept randomized trial
TLDR
A concentration dependent antiviral activity of oral high-dose IVM was identified at a dosing regimen that was well tolerated and large trials with clinical endpoints are necessary to determine the clinical utility of IVM in COVID-19. Expand
IVERMECTIN REPROPOSING FOR COVID-19 TREATMENT OUTPATIENTS IN MILD STAGE IN PRIMARY HEALTH CARE CENTERS
TLDR
Treatment with ivermectin in outpatients with mild stage COVID-19 disease managed to slightly reduce the symptom numbers, and this treatment improved the clinical state to obtain medical release, even in the presence of comorbidities. Expand
Pharmacological Treatment of Patients with Mild to Moderate COVID-19: A Comprehensive Review
TLDR
Treatment of early COVID-19 may be associated with reduced viral load, thus potentially decreasing disease spread in the community, and it is suggested that colchicine, inhaled budesonide, and nitazoxanide, along with nonpharmacological measures, may be used to mitigate the effects of the CO VID-19 pandemic in middle-income countries. Expand
Favorable outcome on viral load and culture viability using Ivermectin in early treatment of non-hospitalized patients with mild COVID-19, A double-blind, randomized placebo-controlled trial.
TLDR
There were significantly lower viral loads and viable cultures in the ivermectin group, which could lead to shortening isolation time in patients at an early stage of COVID19 infection. Expand
Ivermectin for the Treatment of Coronavirus Disease 2019: A Systematic Review and Meta-analysis of Randomized Controlled Trials
TLDR
In comparison to SOC or placebo, IVM did not reduce all-cause mortality, length of stay or viral clearance in RCTs in COVID-19 patients with mostly mild disease, and IVM is not a viable option to treat patients. Expand
Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines
TLDR
Moderate-certainty evidence finds that large reductions in COVID-19 deaths are possible using ivermectin, and the apparent safety and low cost suggest that iverMectin is likely to have a significant impact on the SARS-CoV-2 pandemic globally. Expand
Ivermectin for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials
TLDR
In comparison to SOC or placebo, IVM did not reduce all-cause mortality, length of stay or viral clearance in RCTs in COVID-19 patients with mostly mild disease, and is not a viable option to treat patients. Expand
Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection
Abstract Ivermectin is an antiparasitic drug being investigated for repurposing against SARS-CoV-2. Ivermectin showed in-vitro activity against SARS-COV-2 at high concentrations. This meta-analysisExpand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 36 REFERENCES
Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: A randomized multi-center clinical trial
TLDR
Different doses of ivermectin are evaluated in adult patients with mild COVID-19 and the effect of iVermectIn on mortality and clinical consequences is evaluated. Expand
Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A Randomized-Controlled Trial
TLDR
In patients with mild Covid-19, no benefit was observed with HCQ beyond the usual care and the time to complete resolution of symptoms was shortened. Expand
Controlled randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Baghdad, Iraq
TLDR
Ivermectin with doxycycline reduced the time to recovery and the percentage of patients who progress to more advanced stage of disease and reduced mortality rate in severe patients from 22.72% to 0%; however, 18.2% of critically ill patients died with IvermECTin and doxy cycline therapy. Expand
Efficacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic
Background: Up-to-date, there is no recognized effective treatment or vaccine for the treatment of COVID-19 that emphasize urgency around distinctive effective therapies. This study aims toExpand
Remdesivir for the Treatment of Covid-19 — Final Report
TLDR
The data show that remdesivir was superior to placebo in shortening the time to recovery in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection. Expand
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.
TLDR
Among patients with moderate COVID-19, those randomized to a 10-day course of remdesivir did not have a statistically significant difference in clinical status compared with standard care at 11 days after initiation of treatment, but the difference was of uncertain clinical importance. Expand
Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019
TLDR
Ivermectin treatment was associated with lower mortality during treatment of COVID-19, especially in patients with severe pulmonary involvement, and Randomized controlled trials are needed to confirm these findings. Expand
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
TLDR
In hospitalized adult patients with severe Covid-19, no benefit was observed with lopinavir–ritonavir treatment beyond standard care, and future trials in patients withsevere illness may help to confirm or exclude the possibility of a treatment benefit. Expand
[Ivermectin as an adjunct in the treatment of refractory epilepsy].
TLDR
Ivermectin has been useful as an adjuvant, achieving a significant decrease in seizures in this group of drug resistant patients, and this study is the first to show this effect in refractory epileptic patients. Expand
Safety and mosquitocidal efficacy of high-dose ivermectin when co-administered with dihydroartemisinin-piperaquine in Kenyan adults with uncomplicated malaria (IVERMAL): a randomised, double-blind, placebo-controlled trial.
TLDR
Ivermectin at both doses assessed was well tolerated and reduced mosquito survival for at least 28 days after treatment, and this drug shows promise as a potential new tool for malaria elimination. Expand
...
1
2
3
4
...